Cargando…

Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment

Neuroblastoma (NB) is the most common extracranial malignant solid tumor seen in children and continues to lead to the death of many pediatric cancer patients. The poor outcome in high risk NB is largely attributed to the development of chemoresistant tumor cells. Doxorubicin (dox) has been widely e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Haoyu, Chen, Zhenghu, Hu, Ting, Wang, Long, Yu, Yang, Zhao, Yanling, Sun, Wenijing, Guan, Shan, Pang, Jonathan C., Woodfield, Sarah E., Liu, Qing, Yang, Jianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043366/ https://www.ncbi.nlm.nih.gov/pubmed/27687684 http://dx.doi.org/10.1038/srep34397

Ejemplares similares

Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2016)

Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo
por: Li, Haoyu, et al.
Publicado: (2016)

Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma
por: Mao, Xinfang, et al.
Publicado: (2016)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo
por: Chen, Zhenghu, et al.
Publicado: (2017)

TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2017)

Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling
por: Bieerkehazhi, Shayahati, et al.
Publicado: (2016)

Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway
por: Guo, Kevin Y., et al.
Publicado: (2017)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
por: Smith, David C., et al.
Publicado: (2015)

The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
por: Harris, Michael A., et al.
Publicado: (2020)

Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis
por: Wang, Mopei, et al.
Publicado: (2019)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis
por: Wang, Hao, et al.
Publicado: (2016)

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
por: Augello, Giuseppa, et al.
Publicado: (2018)

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
por: Wang, Yongfeng, et al.
Publicado: (2016)

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
por: Liu, Wei, et al.
Publicado: (2017)

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
por: Gupta, Neeraj, et al.
Publicado: (2017)

Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis
por: Chen, Zhenghu, et al.
Publicado: (2016)

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
por: Assouline, S E, et al.
Publicado: (2014)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
por: Gupta, Neeraj, et al.
Publicado: (2016)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma
por: Sun, Wenjing, et al.
Publicado: (2017)

MELK is a novel therapeutic target in high-risk neuroblastoma
por: Guan, Shan, et al.
Publicado: (2017)

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells
por: Shi, Yonghua, et al.
Publicado: (2016)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia
por: Sánchez, Gina, et al.
Publicado: (2020)

Ixazomib-Associated Skin Exfoliation
por: Zhang, Yali, et al.
Publicado: (2022)

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
por: Parvin, Sultana, et al.
Publicado: (2023)

Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis
por: Fan, Qiaowei, et al.
Publicado: (2017)

Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor
por: Hämmerle, Barbara, et al.
Publicado: (2013)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
por: Gupta, Neeraj, et al.
Publicado: (2017)

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism
por: Chattopadhyay, Nibedita, et al.
Publicado: (2015)

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors
por: Gupta, Neeraj, et al.
Publicado: (2017)

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Sasaki, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ea1b8di2534b5hptom9b2h1tam